☰

Angelo Aguilar, Ph.D. - Publications

Affiliations: 
2008 Department of Chemistry Kansas State University, Manhattan, KS, United States 
Area:
Organic Chemistry
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Xu S, Aguilar A, Huang L, Xu T, Zheng K, McEachern D, Przybranowski S, Foster C, Zawacki K, Liu Z, Chinnaswamy K, Stuckey J, Wang S. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong Antitumor Activity. Journal of Medicinal Chemistry. PMID 32338903 DOI: 10.1021/Acs.Jmedchem.0C00547  0.406
2019 Yang J, Li Y, Aguilar A, Liu Z, Yang CY, Wang S. Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders. Journal of Medicinal Chemistry. PMID 31560543 DOI: 10.1021/Acs.Jmedchem.9B00846  0.403
2019 Aguilar A, Zheng K, Xu T, Xu S, Huang L, Fernandez-Salas E, Liu L, Bernard D, Harvey KP, Foster C, McEachern D, Stuckey J, Chinnaswamy K, Delproposto J, Kampf JW, et al. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. Journal of Medicinal Chemistry. PMID 31244110 DOI: 10.1021/Acs.Jmedchem.9B00021  0.413
2018 Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, Yang CY, Wang M, Han X, Wang S. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. Journal of Medicinal Chemistry. PMID 30525597 DOI: 10.1021/Acs.Jmedchem.8B00909  0.44
2018 Zhao Y, Zhou B, Bai L, Liu L, Yang CY, Meagher JL, Stuckey JA, McEachern D, Przybranowski S, Wang M, Ran X, Aguilar A, Hu Y, Kampf JW, Li X, et al. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. Journal of Medicinal Chemistry. PMID 30015487 DOI: 10.1021/Acs.Jmedchem.8B00483  0.409
2018 Yang J, Li Y, Aguilar A, McEachern D, Przybranowski S, Fernandez-Salas E, Lu J. Abstract 4870: Targeted MDM2 degradation as a novel and efficacious cancer therapy Cancer Research. 78: 4870-4870. DOI: 10.1158/1538-7445.Am2018-4870  0.375
2017 Wang S, Xu S, Aguilar A, Xu T, Zheng K, Huang L, Stuckey J, Chinnaswamy K, Bernard D, Fernández-Salas E, Liu L, Wang M, McEachern D, Przybranowski S, Foster C. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angewandte Chemie (International Ed. in English). PMID 29284071 DOI: 10.1002/Anie.201711828  0.389
2017 Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, Sun D, Wang H, Wen J, Wang G, Zhai Y, et al. Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. Journal of Medicinal Chemistry. PMID 28339198 DOI: 10.1021/Acs.Jmedchem.6B01665  0.428
2017 Wang S, Zhao Y, Aguilar A, Bernard D, Yang CY. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. Cold Spring Harbor Perspectives in Medicine. PMID 28270530 DOI: 10.1101/Cshperspect.A026245  0.414
2015 Lu J, Aguilar A, Zou B, Bao W, Koldas S, Shi A, Desper J, Wangemann P, Xie XS, Hua DH. Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels. Bioorganic & Medicinal Chemistry. 23: 5985-98. PMID 26190460 DOI: 10.1016/J.Bmc.2015.06.055  0.523
2015 Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. Journal of Medicinal Chemistry. 58: 1038-52. PMID 25396320 DOI: 10.1021/Jm501092Z  0.401
2014 Aguilar A, Sun W, Liu L, Lu J, McEachern D, Bernard D, Deschamps JR, Wang S. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. Journal of Medicinal Chemistry. 57: 10486-98. PMID 25496041 DOI: 10.1021/Jm501541J  0.436
2014 Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, Hoffman-Luca CG, Lu J, Shangary S, Yu S, Bernard D, ... Aguilar A, et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Research. 74: 5855-65. PMID 25145672 DOI: 10.1158/0008-5472.Can-14-0799  0.375
2014 Bai L, Chen J, McEachern D, Liu L, Zhou H, Aguilar A, Wang S. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Plos One. 9: e99404. PMID 24901320 DOI: 10.1371/Journal.Pone.0099404  0.414
2013 Aguilar A, Zhou H, Chen J, Liu L, Bai L, McEachern D, Yang CY, Meagher J, Stuckey J, Wang S. A potent and highly efficacious Bcl-2/Bcl-xL inhibitor. Journal of Medicinal Chemistry. 56: 3048-67. PMID 23448298 DOI: 10.1021/Jm4001105  0.449
2012 Chen J, Zhou H, Aguilar A, Liu L, Bai L, McEachern D, Yang CY, Meagher JL, Stuckey JA, Wang S. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. Journal of Medicinal Chemistry. 55: 8502-14. PMID 23030453 DOI: 10.1021/Jm3010306  0.462
2012 Zhou H, Aguilar A, Chen J, Bai L, Liu L, Meagher JL, Yang CY, McEachern D, Cong X, Stuckey JA, Wang S. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. Journal of Medicinal Chemistry. 55: 6149-61. PMID 22747598 DOI: 10.1021/Jm300608W  0.446
2012 Zhou H, Chen J, Meagher JL, Yang CY, Aguilar A, Liu L, Bai L, Cong X, Cai Q, Fang X, Stuckey JA, Wang S. Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold. Journal of Medicinal Chemistry. 55: 5987. PMID 22676037 DOI: 10.1021/Jm300728G  0.346
2012 Zhou H, Chen J, Meagher JL, Yang CY, Aguilar A, Liu L, Bai L, Cong X, Cai Q, Fang X, Stuckey JA, Wang S. Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. Journal of Medicinal Chemistry. 55: 4664-82. PMID 22448988 DOI: 10.1021/Jm300178U  0.437
Show low-probability matches.